Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum
by Zacks Equity Research
Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the Week article.
Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.
5 Stocks to Keep a Tab on for Solid Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed earnings acceleration as of now are Catalyst Pharmaceuticals (CPRX), Warby Parker (WRBY), MakeMyTrip (MMYT), Brookfield Renewable Partners (BEP) & Century Aluminum (CENX).
Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Catalyst's (CPRX) Q1 Earnings Lag, Sales Boost Revenues
by Zacks Equity Research
Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $16.60, moving -0.12% from the previous trading session.
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.
Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $15.76, marking a -1.62% move from the previous day.
3 Reasons Growth Investors Will Love Catalyst (CPRX)
by Zacks Equity Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed at $16.52 in the latest trading session, marking a +0.24% move from the prior day.
Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.82, moving -1.44% from the previous trading session.
Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.78, marking a -0.94% move from the previous day.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
by Zacks Equity Research
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
by Zacks Equity Research
Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.